RAD51 knockdown also sensitized BRCA-proficient MDA-MB-231 and SUM159 cells to olaparib [51], implying that a combination of RAD51i and PARPi can be used as a strategy to target HR-proficient cancers [35,52,70]. The gene discussed is RAD51; the disease is cancer.